Skip to main content
Clinical Trials/JPRN-jRCT1031180386
JPRN-jRCT1031180386Active, not recruiting未知

Comparison of Dapagliflozin and vitamin E Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, Open-Label Controlled Trial

Ikejima Kenichi0 sites40 target enrollmentStarted: March 20, 2019Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Active, not recruiting
Sponsor
Enrollment
40

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 20age old to <= 80age old (—)
Sex
All

Inclusion Criteria

  • HbA1c>=6.5% after dietary exercise during pre-observation period (8 to 16 weeks), hepatic steatosis in abdominal US

Exclusion Criteria

  • 1.ethanol consumption over 30g/d in Male or 20g/d in Female
  • 2.type 1 diabetic patients
  • 3. poor glycemic control HbA1c>=8.4%
  • 4.patients who are being treated for liver disease other than NAFLD
  • 5.Male: serum creatinine higher than 1.2mg/dL Female: serum creatinine higher than 1.0mg/dL patients
  • 6.Patients who cannot be aware of dry mouth
  • 7.SGLT2 inhibitor contraindication case
  • 8.Patients with a history of hypersensitivity to SGLT2 inhibitor/Vit. E
  • 9.Patients judged to be ineligible by a doctor

Investigators

Sponsor
Ikejima Kenichi

Similar Trials